QQQ   432.44 (+0.32%)
AAPL   169.87 (-1.63%)
MSFT   416.80 (+0.76%)
META   502.29 (+0.41%)
GOOGL   155.22 (+0.23%)
AMZN   184.12 (+0.27%)
TSLA   156.52 (-3.07%)
NVDA   880.22 (+2.35%)
AMD   164.03 (+2.31%)
NIO   3.86 (-0.77%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.19 (-0.33%)
MU   122.19 (+0.68%)
GE   156.73 (+1.97%)
CGC   6.76 (-3.15%)
DIS   114.06 (+0.98%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.18 (-0.42%)
QQQ   432.44 (+0.32%)
AAPL   169.87 (-1.63%)
MSFT   416.80 (+0.76%)
META   502.29 (+0.41%)
GOOGL   155.22 (+0.23%)
AMZN   184.12 (+0.27%)
TSLA   156.52 (-3.07%)
NVDA   880.22 (+2.35%)
AMD   164.03 (+2.31%)
NIO   3.86 (-0.77%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.19 (-0.33%)
MU   122.19 (+0.68%)
GE   156.73 (+1.97%)
CGC   6.76 (-3.15%)
DIS   114.06 (+0.98%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.18 (-0.42%)
QQQ   432.44 (+0.32%)
AAPL   169.87 (-1.63%)
MSFT   416.80 (+0.76%)
META   502.29 (+0.41%)
GOOGL   155.22 (+0.23%)
AMZN   184.12 (+0.27%)
TSLA   156.52 (-3.07%)
NVDA   880.22 (+2.35%)
AMD   164.03 (+2.31%)
NIO   3.86 (-0.77%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.19 (-0.33%)
MU   122.19 (+0.68%)
GE   156.73 (+1.97%)
CGC   6.76 (-3.15%)
DIS   114.06 (+0.98%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.18 (-0.42%)
QQQ   432.44 (+0.32%)
AAPL   169.87 (-1.63%)
MSFT   416.80 (+0.76%)
META   502.29 (+0.41%)
GOOGL   155.22 (+0.23%)
AMZN   184.12 (+0.27%)
TSLA   156.52 (-3.07%)
NVDA   880.22 (+2.35%)
AMD   164.03 (+2.31%)
NIO   3.86 (-0.77%)
BABA   69.99 (-0.89%)
T   16.04 (-1.23%)
F   12.19 (-0.33%)
MU   122.19 (+0.68%)
GE   156.73 (+1.97%)
CGC   6.76 (-3.15%)
DIS   114.06 (+0.98%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.18 (-0.42%)
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

$19.45
-0.29 (-1.47%)
(As of 03:09 PM ET)
Today's Range
$18.75
$20.26
50-Day Range
$18.95
$24.23
52-Week Range
$5.63
$26.35
Volume
1.16 million shs
Average Volume
248,051 shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.25

NewAmsterdam Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
68.8% Upside
$33.25 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of NewAmsterdam Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$4.10 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.89) to ($1.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

385th out of 930 stocks

Pharmaceutical Preparations Industry

171st out of 428 stocks

NAMS stock logo

About NewAmsterdam Pharma Stock (NASDAQ:NAMS)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Stock Price History

NAMS Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma prices $175M share offering
See More Headlines
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/16/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NAMS
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.25
High Stock Price Target
$37.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+68.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.09 million
Book Value
$3.50 per share

Miscellaneous

Free Float
87,035,000
Market Cap
$1.76 billion
Optionable
Not Optionable
Beta
0.02
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Michael Harvey Davidson FACC (Age 68)
    Facp., M.D., CEO, President, Executive Board Member & Director
    Comp: $882k
  • Dr. Johannes Jacob Pieter Kastelein FESC (Age 70)
    M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director
    Comp: $677.76k
  • Mr. Mayur Amrat Somaiya (Age 51)
    Chief Financial Officer
    Comp: $130.58k
  • Mr. Douglas F. Kling (Age 51)
    Chief Operating Officer
  • Mr. Jim Jacobson
    Chief Legal Officer & Secretary
  • Dr. Marc Ditmarsch M.D. (Age 57)
    Chief Development Officer
  • Dr. Sheng Cui Ph.D.
    VP & Head of Chemistry Manufacturing and Controls (CMC)
  • Ms. Annie Neild
    VP & Head of Regulatory Affairs
  • Mr. William Jones Jr. (Age 60)
    M.B.A., Chief Commercial Officer

NAMS Stock Analysis - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings
or view top-rated stocks.

What is NewAmsterdam Pharma's stock price target for 2024?

5 brokers have issued twelve-month target prices for NewAmsterdam Pharma's shares. Their NAMS share price targets range from $30.00 to $37.00. On average, they anticipate the company's stock price to reach $33.25 in the next twelve months. This suggests a possible upside of 68.8% from the stock's current price.
View analysts price targets for NAMS
or view top-rated stocks among Wall Street analysts.

How have NAMS shares performed in 2024?

NewAmsterdam Pharma's stock was trading at $11.17 at the start of the year. Since then, NAMS shares have increased by 76.4% and is now trading at $19.70.
View the best growth stocks for 2024 here
.

When is NewAmsterdam Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our NAMS earnings forecast
.

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Yarbrough Capital LLC (0.03%). Insiders that own company stock include James N Topper, Johannes Jacob Piete Kastelein and Louis G Lange.
View institutional ownership trends
.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAMS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners